Study Of Atopic Dermatitis In Pediatrics
Phase 3
Completed
- Conditions
- Dermatitis, Atopic
- Registration Number
- NCT00257569
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
To verify of cetirizine dry syrup to ketotifen dry syrup in the change in the severity of pruritus of the treatment period.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 278
Inclusion Criteria
- Children diagnosed as atopic dermatitis
- Giving informed consent
- Children who have 2 grades or more pruritus score.
- Children who require the treatment with external steroid preparation other than face and head.
- Children with a pruritus severity of 2.
- Mild or severe on the fist day of the treatment period.
Exclusion criteria:
- have spastic disease such as epilepsy
- have a history of drug hypersensitivity
- are lactating or possibly pregnant female Children
- have a skin infection, or with zooparasite such as scabies and pediculosis
- cannot avoid the use of external steroid classified into strong, strongest or very strong
- have eczematous otitis externa with perforation in the eardrum
- have dermal ulcer, or profound heat burn or frostbite of the severity higher than the grade 2
- have asthma that requires the treatment with corticosteroid
- have pruritus only on face and head
- have inappropriate complication of dermal disorder that may influence on the evaluation of the study drug
- are undergoing specific desensitization therapy or immunomodulation therapy or phototherapy.
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method change in the severity of pruritus
- Secondary Outcome Measures
Name Time Method -changes in the total pruritus score -daily main pruritus score -improvement of area with pruritus -patient global improvement -Cetirizine serum concentrations -Adverse events
Trial Locations
- Locations (1)
GSK Investigational Site